Rhythm Pharmaceuticals (RYTM) Debt to Equity (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) has disclosed Debt to Equity for 5 consecutive years, with $0.78 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 84.61% to $0.78 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.78, a 84.61% decrease, with the full-year FY2025 number at $0.78, down 84.61% from a year prior.
- Debt to Equity was $0.78 for Q4 2025 at Rhythm Pharmaceuticals, up from $0.73 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $5.78 in Q1 2025 to a low of -$9.22 in Q2 2025.
- A 3-year average of $0.62 and a median of $0.76 in 2025 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: soared 708.25% in 2024, then plummeted 84.61% in 2025.
- Rhythm Pharmaceuticals' Debt to Equity stood at $0.63 in 2023, then skyrocketed by 708.25% to $5.05 in 2024, then tumbled by 84.61% to $0.78 in 2025.
- Per Business Quant, the three most recent readings for RYTM's Debt to Equity are $0.78 (Q4 2025), $0.73 (Q3 2025), and -$9.22 (Q2 2025).